Key result
Novel 8-variable model predicts T2D kidney progression, identifying high-risk patients who gain ~3.5% absolute benefit from dapagliflozin.
Cohort (n=41,204)
Answers are grounded in this paper and cite their sources.
OBJECTIVE: To develop a risk assessment tool to identify patients with type 2 diabetes (T2D) at higher risk for kidney disease progression and who might benefit more from sodium-glucose cotransporter 2 (SGLT2) inhibition. RESEARCH DESIGN AND METHODS: A total of 41,204 patients with T2D from four Thrombolysis In Myocardial Infarction (TIMI) clinical trials were divided into derivation (70%) and validation cohorts (30%). Candidate predictors of kidney disease progression (composite of sustained ≥40% decline in estimated glomerular filtration rate [eGFR], end-stage kidney disease, or kidney death) were selected with multivariable Cox regression. Efficacy of dapagliflozin was assessed by risk categories (low: <0.5%; intermediate: 0.5 to <2%; high: ≥2%) in Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58. RESULTS: There were 695 events over a median follow-up of 2.4 years. The final model comprised eight independent predictors of kidney disease progression: atherosclerotic cardiovascular disease, heart failure, systolic blood pressure, T2D duration, glycated hemoglobin, eGFR, urine albumin-to-creatinine ratio, and hemoglobin. The c-indices were 0.798 (95% CI, 0.774-0.821) and 0.798 (95% CI, 0.765-0.831) in the derivation and validation cohort, respectively. The calibration plot slope (deciles of predicted vs. observed risk) was 0.98 (95% CI, 0.93-1.04) in the validation cohort. Whereas relative risk reductions with dapagliflozin did not differ across risk categories, there was greater absolute risk reduction in patients with higher baseline risk, with a 3.5% absolute risk reduction in kidney disease progression at 4 years in the highest risk group (≥1%/year). Results were similar with the 2022 Chronic Kidney Disease Prognosis Consortium risk prediction model. CONCLUSIONS: Risk models for kidney disease progression can be applied in patients with T2D to stratify risk and identify those who experience a greater magnitude of benefit from SGLT2 inhibition.
No takes yet. Share an insight, caveat, or question.
Moura et al. (2023) conducted a cohort in Type 2 diabetes (n=41,204). Dapagliflozin and 8-variable kidney disease progression risk model vs. Lower baseline predicted risk categories was evaluated on Kidney disease progression (composite of sustained ≥40% decline in eGFR, end-stage kidney disease, or kidney death) (c-index 0.798, 95% CI 0.765-0.831). An 8-variable risk model predicted kidney disease progression in T2D, with dapagliflozin yielding a 3.5% ARR at 4 years in the highest-risk group.
Synapse has enriched 10 related papers. Consider them for comparative context: